11月20日（路透社） - 诺华制药（NOVARTIS AG）发布消息称，预计2025-2030年的销售复合年增长率（CAGR）将达到+5-6%，长期增长受益于30多项潜在高价值的管线资产。 *KISQALI和SCEMBLIX的高峰销售指导上调；诺华目前拥有八项风险降低的市场在售资产，预计高峰销售潜力在30亿至100亿美元之间。*预计未来两年将有15项以上的可能提交的数据发布，以支持长期增长。*管线包括30多种潜在高价值的药物，其中10种以上在过去两年内获得许可或收购。*展望：预计到2029年将恢复至40%以上的利润率。*计划收购Avidity Biosciences预计将在2026年上半年完成。*KISQALI的销售指导从80亿美元上调至100亿美元以上；SCEMBLIX的销售指导从30亿美元上调至40亿美元以上。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.